Radionuclide News and Research

RSS

Researchers reveal new approach to precisely identify and treat prostate cancer

Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects.

7 Sep 2017

New study invalidates concerns about radioactivity in migratory marine predators

When the Fukushima power plant released large quantities of radioactive materials into nearby coastal waters following Japan's massive 2011 earthquake and tsunami, it raised concerns as to whether eating contaminated seafood might impair human health--not just locally but across the Pacific.

31 Aug 2017

SNMMI recognizes contributions to nuclear medicine and molecular imaging at 2017 annual meeting

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2017 Annual Meeting in Denver, Colorado. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.

2 Aug 2017

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life.

13 Jun 2017

ICNC 2017 to unveil future applications of nuclear cardiology and cardiac CT imaging

Future applications of nuclear cardiology and cardiac computed tomography (CT) imaging are set to be revealed at the International Conference on Nuclear Cardiology and Cardiac CT 2017.

10 Apr 2017

Targeted alpha therapy shows promise in treatment of metastatic prostate cancer

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer.

21 Dec 2016

3D-printed organ models could aid individualized dosimetry in nuclear medicine

In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images.

6 Dec 2016

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.

17 Oct 2016

New, portable molecular imaging system combines optical imaging and scintigraphy

Bigger isn't always better, especially when it comes to a new and surprisingly portable molecular imaging system that combines optical imaging at the surface level and scintigraphy, which captures the physiological function of what lies beneath, announced developers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

15 Jun 2016

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers.

15 Jun 2016

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates.

14 Jun 2016

Genetic blood test can help predict patient’s respone to neuroendocrine cancer therapy

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, an investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy (PRRT) before they commit to a course of treatment.

14 Jun 2016

Novel radioimmunotherapy may help cure colorectal cancer

An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.

14 Jun 2016

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.

11 Mar 2016

Advances in the field of MPI: an interview with Professor Kannan Krishnan

In around 2004, there was a Phillips paper that discussed a new imaging technique called MPI. At that time, I had an eager, promising graduate student named Matt Ferguson who wanted a project, so I asked him to take a look.

From Bruker BioSpin - NMR, EPR and Imaging 1 Mar 2016

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Interview conducted with Professor Björn Wängler, Professor for Molecular Imaging and Radiochemistry from Heidelberg University.

From Bruker BioSpin - NMR, EPR and Imaging 4 Feb 2016

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

7 Oct 2015

Preclinical Magnetic Particle Imaging: an interview with Professor Jeff Bulte, Johns Hopkins

I'm Jeff Bulte, professor of Radiology and Director of Cellular Imaging at the Institute for Cell Engineering at Johns Hopkins University School of Medicine, Baltimore, Maryland in the United States. I lead a group of about 20 to 25 people who focus their research on imaging cells.

From Bruker BioSpin - NMR, EPR and Imaging 24 Jun 2015

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Prostate-specific membrane antigen (PSMA) is a surface protein that is normally present on healthy prostate cells, but is found at much higher levels on prostate cancer cells. It is barely found in the rest of the body. "Therefore, PSMA is an ideal target for diagnostic purposes as well as targeted therapies against prostate cancer," says biotechnologist Dr. Matthias Eder of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

23 Jun 2015

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Baseline right ventricular ejection fraction as evaluated by conventional planar equilibrium radionuclide angiography is significantly associated with outcomes in patients with pulmonary arterial hypertension, research suggests.

13 Feb 2015

Radionuclide News and Research

Researchers reveal new approach to precisely identify and treat prostate cancer

New study invalidates concerns about radioactivity in migratory marine predators

SNMMI recognizes contributions to nuclear medicine and molecular imaging at 2017 annual meeting

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

ICNC 2017 to unveil future applications of nuclear cardiology and cardiac CT imaging

Targeted alpha therapy shows promise in treatment of metastatic prostate cancer

3D-printed organ models could aid individualized dosimetry in nuclear medicine

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

New, portable molecular imaging system combines optical imaging and scintigraphy

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Genetic blood test can help predict patient’s respone to neuroendocrine cancer therapy

Novel radioimmunotherapy may help cure colorectal cancer

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

Advances in the field of MPI: an interview with Professor Kannan Krishnan

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Preclinical Magnetic Particle Imaging: an interview with Professor Jeff Bulte, Johns Hopkins

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News